NCT03452345View on ClinicalTrials.gov

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

April 16, 2019

Conditions
Masseter Muscle Hypertrophy
Interventions
DRUG

Meditoxin

Meditoxin (Botulinum toxin type A)

DRUG

Placebo

Placebo (Normal saline)

Trial Locations (1)

03181

Kangbuk Samsung Hospital, Seoul

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03452345 - MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy | Biotech Hunter | Biotech Hunter